DENGUE CASE INVESTIGATION REPORT



CDC Dengue Branch and Puerto Rico Department of Health 1324 Calle Cañada, San Juan, P. R. 00920-3860 Tel. (787) 706-2399, Fax (787) 706-2496

Form Approved OMB No. 0920 Tel. (787) 706-2399, Fax (787) 706-2496 Exp. Date 03/31/2017 FOR CDC DENGUE BRANCH USE ONLY Case number Specimen # Days post onset (DPO) Type Date Received Specimen # Days post onset (DPO) Type Date Received SAN ID GCODE **S4 S2** Please read and complete ALL sections Hospitalized due to this illness: No → Hospital Name: **Record Number: Patient Data** Yes Fatal: Name of Patient: Yes No Unk Last Name First Name Middle Name or Initial Mental status changes: If patient is a minor, name of father or primary caregiver: Yes No Unk Last Name First Name Middle Name or Initial Home (Physical) Address Physician who referred this case Name of Healthcare Provider: Email: Tel: Send laboratory results to (mailing address): City: Zip code: Tel: Other Tel: Residence is close to: Work address: Who filled out this form? Patient's Demographic Information Date of Birth: Age: _month Sex: Name (complete): years Pregnant: Y or Age: Weeks pregnant (gestation): Must have the following information for sample processing Modified Variables for AZ investigation Duration of hospitalization (days)? Date of first symptom: Country of birth Admitted to the ICU? Yes No Date specimen taken: Serum: First sample (Acute = first 5 days of illness – check for virus) Duration of ICU admission (days): Sought care in Mexico? Yes No Unk Second sample (Convalescent = more than 5 days after onset – check for antibodies) During the 14 days before onset of illness, did you TRAVEL to other cities or countries? Yes, another country Yes, another city No Third sample WHERE did you TRAVEL? Fatal cases (tissue type): PLEASE indicate below the signs and symptoms that the patient had at any time during the illness for which they sought care Evidence of capillary leak Warning signs Unk Lowest hematocrit (%) Persistent vomiting.. Fever in 7 days before visit..... Highest hematocrit (%) Abdominal pain/Tenderness..... Fever during visit..... Mucosal bleeding Lowest serum albumin Platelets ≤100.000/mm³..... Lethargy, restlessness..... Lowest serum protein Liver enlargement >2cm..... Lowest platelet count: Lowest blood pressure (SBP/DBP) Pleural or abdominal effusion..... Lowest pulse pressure (systolic - diastolic) Any hemorrhagic manifestation Petechiae..... Lowest white blood cell count (WBC) Additional symptoms Purpura/Ecchymosis..... Symptoms Unk Diarrhea..... Vomit with blood..... Rapid, weak pulse..... Cough..... Blood in stool..... Pallor or cool skin..... Conjunctivitis..... Nasal bleeding..... Chills..... Nasal congestion..... Bleeding gums..... Sore throat..... Blood in urine..... Headache..... Jaundice..... Vaainal bleedina..... Eye pain..... Convulsion or coma..... Positive urinalysis..... Body (muscle/bone) pain...... Nausea and vomiting (occasional).... (over 5 RBC/hpf or positive for blood) Joint pain..... Arthritis (Swollen joints).....

Anorexia.....

Tourniquet test Pos Neg Not done

SOUTHERN ARIZONA HOUSEHOLD DENGUE INVESTIGATION

HOUSEHOLD ENROLLMENT FORM		Date of visit (M Team number:	M/DD /YYYY):/ 	
Complete one form for each household.				
1. Cluster ID# - Household ID# :				
2. Phone number (Número de Teléfono	o):	· · · · · · · · · · · · · · · · · · ·		
3. Household Latitude: 32°	′N Longitı	ude: 114º	′W	
List all individuals who slept in the hou	se last night <u>and</u> :	sleep in the hou	use regularly in the l	ast 3
months, starting with the head of hous	sehold.			
If there are not enough spaces, please v	vrite the additiona	al information b	elow this section.	
			Individual ID#	
A	Age: yr	s □M □F		□ Blood
B	Age: yr	s □M□F		□ Blood
C	Age: yr	s □M□F		□ Blood
D	Age: yr	s ¬M ¬F		□ Blood
E	Age : yr	s □M □F		□ Blood
F	Age : yr	s □M □F		□ Blood
G	Age : yr	s □M □F		□ Blood
H	Age: yr	s □M □F		□ Blood
l	Age: yr	s □M □F		□ Blood
J	Age: yr	s □M □F		□ Blood
K	Age: yr	s □M □F		□ Blood
L	Age : yr	s □M□F		□ Blood
M	Age: yr	s □M □F		□ Blood

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

^{*}Individual ID refers to the [cluster ID # - household ID # - individual id #] (e.g. 008 – 01 – 05)

4. Describe structure of the home (Describa la estructura de la casa): ☐ Mobile home or
trailer/Casa móvil \square RV \square Single Family Dwelling/domicilio de una sola familia \square Duplex or
Four-plex
niveles □Temporary shelter/Refugio temporal □Other:
5. What is the source of household water supply? De donde obtiene el agua de su casa?
☐ Piped/Public - público ☐ Well/Pozo ☐ Rain water/agua de lluvia
\square Water tank/tanque de agua (Diamond Brooks) \square Unknown/no se
□Other:
6. In the last 3 months do you store water in open containers on your property? En los últimos 3 meses tiene usted agua almacenada en envases/depositos abiertos dentro de su
propiedad?: □Yes □ No □ Don't know
7. Have you had any visitors that have traveled from out of the country, for example Mexico, in the last three months? <i>En los últimos 3 meses ha tenido usted visitantes de otro país, por</i>
ejemplo de México? ☐ Yes ☐ No ☐ Unknown
If YES 7a. Where did they travel from? De que país vinieron?
☐ Mexico ☐ Other country:
8. Has anyone in your household including visitors had a fever while residing in the house in the last three months? Alguna persona en su casa ha tenido fiebre en los últimos tres meses?
☐ Yes ☐ No ☐ Unknown
9. Does your home have window screens? Tiene su casa mosquiteros en las ventanas ?
☐ On all windows ☐ On some windows ☐ On no windows ☐ Unknown
10. In the last 3 months do you leave your windows open? <i>En los últimos 3 meses usted deja sus ventanas abiertas? Note:</i> If windows only rarely or sometimes left open, please check "no."
\square Yes, At night and during day \square Yes, at night \square Yes, during the day \square No \square Unknown

10b. If yes, how often do you leave your windows open? Si es asi, con que frequencia deja sus ventanas abiertas?

Note: If different frequency at different time, pick highest frequency. I.e., if day is always and nightrarely, check always.

☐ Rarely ☐ Sometimes ☐ Usually ☐ Always ☐ Unknown
11. In the last 3 months what methods do you use to cool your home? <i>En los últimos 3 meses que metodos usa para enfriar su casa?</i>
\square Swamp cooler(cooler) \square AC (window unit or central air) \square Nothing \square Unknown
12. In the past 3 months have you seen mosquitos in your home? En los últimos 3 meses ha
visto mosquitos dentro de su casa? ☐ Yes ☐ No ☐ Unknown
13. In the last 3 months which of the following methods have you used to control mosquitos in or around your home? <i>En los últimos 3 meses cual de los siguientes metodos ha usado para controlar mosquitos dentro o alrededor su casa?</i>
\Box Sprayed own house \Box Professional sprayed house \Box Fogging by Health Department
☐ Mosquito coils ☐ Citronella ☐ None ☐ Unknown
13. Do you have a septic tank? Tiene fosa septica?
☐ Yes ☐ No ☐ Unknown
NOTES:

SOUTHERN ARIZONA HOUSEHOLD DENGUE INVESTIGATION

IMMATURE MOSQUITO SURVEY FORM Complete one form for each household.	Date of visit (MM/DD/YYYY):/ / 2014_ Team number:
Case Patient ID Number ID #:	

		Number of containers (indoors)			
			Wet – water present		
Container		Dry	Larvae/pupae	Larvae/pupae	
ID	Type of Container		absent	present	
1	Bucket				
2	Tire				
3	Water Drum				
4	Plastic container				
5	Aluminum can				
6	Styrofoam				
7	Jar				
8	Flowervase				
9	Septictank				
10	Animal watering pan				
11	Potted plant				
12	Bird Bath/Fountains				
13	Other artificial				
	container:				
14	Tree:				
15	Toys				
16	Pools				
17	Sewers				
17	Bamboo				
18	Other – natural				
17	container (specify)				
20	Tarps				

Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currentlyvalid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

SOUTHERN ARIZONA HOUSEHOLD DENGUE INVESTIGATION

INDIVIDUAL INTERVIEW FORM		Specimen Label	
Team number:	Language of intervi	ew: □ Spanish □ English	Other:
Complete one form for each	n consenting individual in th	e household.	
1. Case Patient ID # - Hou	ısehold ID# - Individual :	#:	
2. Your name <i>Nombre</i> : _			
	First (given)	Middle	Last
3. How long have you be years	en living in Arizona? <i>Cua</i>	ínto tiempo ha estado v	iviendo en Arizona?
4. Have you used mosqu	ito repellent in the past	three months? <i>Ha usado</i>	repelente de
mosquitos en los últimos	tres meses? ☐ Yes ☐	No □ Unknown	
5. Have you traveled out months? <i>Ha viajado uste</i>	•	•	•
☐ Yes ☐ No ☐ Don'	t know		
5a. If you have tra Mexico, con que frecuen	aveled to Mexico, how o cia?	ften do you travel to Me	exico? Si ha viajado a
☐ Daily	□ Weekly □ Monthly	☐ Yearly	
	ed <u>monthly</u> or <u>yearly, fill o</u> most recent travel.	out box below. If yes, sp	ecify when and

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

	Dates of Travel Fechas del viaje (e.g. Dec 2012–Jan 2013)	Duration of travel Duración del viaje (weeks)
Country 1		
Country 2		
Country 3		
Country 4		
Country 5		

]
6. Have you had a fe	ever in the la	st three months? H	la tenido u	sted fiebre en la	os últimos tres
<i>meses</i> ?□ Yes □ N	lo 🗆 Multij	ole □ Don't know			
Note: If respondent another copy of the		,			0
6a. First day	of fever. <i>Pri</i>	mer dia con fiebre (MM/DD/Y	YYY) /	/
6b. Did you	seek medical	attention (e.g. dod	tor, pharn	nacist, healer, et	c.)? Buscó usted
atención mé	dica (doctor,	farmaceutico, cura	andero, eta	:.)? □ Yes □ N	o □Unknown
	•	is the name of the l édica, cual es el nor		•	you sought care?
□ Yu	ıma Regiona	l Medical Center □	Sunset Co	mmunity Health	Center
□ Pri	ivate physici	an □ Urgent care □	☐ Mexico	□ Unknown	
□ 0:	ther				
6b-2. con Dengue?	•	you diagnosed with	h Dengue?	' Si es asi, le han	diagnosticado
	□ Yes □	No			
6b-3.	Were you h	ospitalized for this	illness? <i>Es</i>	tuvo usted hospi	talizado por
esta (enfermedad:	?□ Yes □ No □	Unknown		
		ration of hospitaliza days spital Name. <i>Nombi</i>		•	talización

6c. During your illness, did you have any of the following:

	Yes	No	Unknown	Comments
Headache / Dolor de la cabeza				
Body/muscle pain / Dolor del cuerpo o los				
musculos				
Eye pain/ Dolor de los ojos				
Rash / Erupcion de la piel				
Weakness /Cansancio				
Lack of Appetite / Falta de appetito				
Nausea/vomiting / Nausea/vomito				
Dizziness / Mareos				
Severe persistent abdominal pain / Dolor				
abdominal severo y persistente				
Persistent vomiting (≥3 times in 1 day) /				
Vómito persistente				
Bruising / Moretones				
Nose Bleeding / Sangrado nasal				
Bleeding from gums / Sangrado en las				
encías				
Blood in vomitus / Vomito con sangre				
Blood in urine / Sangre en la orina				
Blood in stool / Sangre en el excremento				
Black, tarry stools / Excreta negra				
Heavy vaginal bleeding / Sangrado				
vaginal excesivo				

7. How do you pay for medical care? Como paga por su cuidado medico?
\square Travel to Mexico and pay out of pocket \square Travel to Mexico and use employer insurance \square AHCCCS
□VA/Military/TriCare □Employer/private insurance □Don't access medical care □Other
Comments:

Dengue Household Investigation in Arizona — Consent Form

The Arizona Department of Health Services and the U.S. Centers for Disease Control and Prevention (CDC) are investigating an illness called "dengue" that is spread by mosquitoes. There have been several cases of dengue in your community. We are trying to find out if the virus that causes dengue has been circulating locally. We are asking volunteer adults and children to answer a short survey and to have their blood drawn by a doctor or nurse and tested to see if they have had dengue. This investigation will help us learn what steps we need to take to prevent more dengue cases in your community.

If you agree, we will draw a small amount of blood – about 2 teaspoons – through a needle in your arm. We will test your blood to see if you have been exposed to dengue, and to see if you currently have dengue virus in your blood. We will tell you your test results in about a month. The blood draw may hurt a little. Some people may have bruising or bleeding at the needle site; some people feel dizzy when they have their blood drawn.

We will ask you to answer a brief survey. The survey will include questions about your health and recent activities, and about your household.

We will give you information about dengue, including tips for how to avoid dengue. Tips include avoiding mosquito bites by using mosquito repellent and wearing long sleeved shirts and pants, and emptying or covering water containers where mosquitoes breed. Also, if you have an illness that you think may be dengue, you should seek medical care immediately.

Taking part in this survey is voluntary.

If you choose to take part, you may stop at any time. We will keep your information private, to the extent allowed by law. There is no cost to you for taking part in this survey.

We are happy to answer any questions or concerns about the investigation. You may also contact the Yuma County Department of Health. Their phone number is 928-317-4550. We will give you a copy of this form to keep for your records.

Your blood sample will be sent to the CDC for testing. If any blood is left over after the tests are done, the CDC would like to store the remaining sample, if you agree. Stored samples may be used for future testing related to dengue or other similar illnesses, or for public health investigations that are relevant to your community.

	I agree to allow my blood specimen to be n Dengue Branch.	e stored at the Centers for Disease Control
Your signature	9:	Date

Public reporting burden of this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011).

Investigación de dengue en hogares de Arizona-Forma de consentimiento

El Departamento de Servicios de Salud de Arizona y los Centros de Control y Prevención de Enfermedades (CDC) están investigando una enfermedad llamada dengue, que se transmite por mosquitos. Han habido varios casos de dengue en su comunidad. Estamos intentando investigar si el virus que causa dengue ha estado circulando localmente. Estamos pidiendo a voluntarios (adultos y niños) responder una breve encuesta y darnos una muestra de sangre tomada por un médico o enfermero/a. Es una prueba para ver si han tenido dengue. Esta investigación nos ayudará a decidir que acciones son necesarias para prevenir más casos de dengue en su comunidad.

Si está de acuerdo, tomaremos una pequeña muestra de sangre – unas dos cucharillas- de su brazo con una jeringa. Vamos a examinar la sangre para ver si usted ha sido expuesto/a a dengue, y para ver si usted en este momento tiene el virus del dengue en su sangre. Le comunicaremos los resultados de la prueba en un mes aproximadamente. El sacar de la sangre puede dolerle un poco. A algunas personas les puede causar moretones o salir un poco de sangre en el lugar del pinchazo; algunas personas pueden marearse cuando se les saque sangre.

Le pediremos que responda a una encuesta breve. La encuesta incluye preguntas sobre su salud, y actividades recientes y sobre su hogar. Le entregaremos información sobre dengue incluyendo sugerencias de como evitar la enfermedad. Las sugerencias incluyen evitar la picadura del mosquito usando repelente para mosquitos, llevar camisas de manga larga y pantalones, y vaciar o cubrir contenedores de agua donde los mosquitos se reproducen. También, si tiene una enfermedad que crea pueda ser dengue, le recomendamos buscar atención medica inmediatamente.

La participación en esta encuesta es voluntaria. Si decide participar, usted puede dejar de contestar en cualquier momento. Toda la información la mantendremos privada hasta el punto permitido por la ley. Participar en esta encuesta no tiene ningún costa para usted.

Estamos a su disposición para responder a cualquier pregunta o preocupación que tenga sobre esta investigación. También puede contactar al Departamento de Servicios de Salud del condado de Yuma. Su numero de teléfono es 928-317-4550. Le entregaremos una copia de este documento para que usted la guarde.

Su muestra de sangre será enviada al CDC para las pruebas. La muestra puede no usarse completamente y de ser así, el CDC quisiera almacenarla, si usted esta de acuerdo. Las muestras de sangre almacenadas podrían usarse para otras pruebas en el futuro relacionados con dengue u otras enfermedades similares, o para investigaciones de salud publica importante para su comunidad. No se harán pruebas de las muestras para condiciones genéticas o para evidencia de infección con VIH.

□ Si □ No Dengue de los	Estoy de acuerdo en permitir que mi muestra de sangre sea almacenada en la Subdivisión de s Centros de Prevención y Control de Enfermedades (CDC).
Firma:	Fecha

Public reporting burden of this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011).

Dengue Household Investigation in Arizona —Children Assent Form

You may have heard of the dengue virus. We are doing an investigation to find out if people living in this neighborhood have had this infection, which comes from mosquito bites. We would like you to be in this investigation. You don't have to be in the investigation unless you want to. It is up to you.

What will happen?

If you let us, we will take a small amount of blood from you by putting a needle in your arm for a few seconds. First we will rub your skin with alcohol to clean it.

Will it hurt?

The needle stick in your skin may hurt a little for a few seconds.

Why are we doing this investigation?

This blood test is being done for this investigation. It is not necessary for you. We are not doing it because you are sick. It will tell us if you had dengue virus in your blood. We will tell you and your parents what we find out.

You can say, 'No'

You can say, 'No' and we won't do the blood test. You will not be in trouble if you say, 'No.' Would you like to participate?

Parental permission

If you agree allow your child to participate in this investigation, please check on of the boxes below regarding storage of your blood specimen, and sign or make your mark below:

□ Yes □ No I agree to allow my blood specimen to be Prevention Dengue Branch.	e stored at the Centers for Disease Control and
Your signature:	Date

Investigación de dengue en hogares de Arizona-

Forma de consentimiento para niños

Puede que hayas escuchado sobre el virus del dengue. Estamos haciendo una investigación para averiguar si personas que viven en este barrio han tenido esta infección, causada por la picadura de mosquitos. Quisiéramos que participaras en esta investigación. No estás obligado a participar si no quieres. Es tu decisión.

¿Qué va a pasar?

Si nos lo permite, te vamos a sacar una muestra de sangre pinchándote con una aguja en tu brazo por unos segundos. Primero, vamos a frotarte la piel con alcohol para limpiarla.

¿Me va a doler?

El pinchazo de la aguja en tu piel puede dolerte un poco por unos segundos.

¿Por qué estamos haciendo esta investigación?

No la estamos haciendo porque estés enfermo, estamos haciendo esta prueba solo para esta investigación, no porque la necesites. La prueba nos dirá si tú has tenido el virus de dengue. Te diremos los resultados a ti y a tus padres.

Tu puedes decir 'NO'

Tu puedes o	lecir 'no' y no te va a causar ningún problema. Quisieras participar?
Permiso de	etus padres
Si está de ao las opcione	cuerdo en permitir que su hijo participe en esta invest <mark>igación.</mark> Por favor, firme y marque una de s.
	Estoy de acuerdo en permitir que la muestra de sangre de mi hijo se almacene en la de Dengue de los Centros de Control y Prevención de Enfermedades.
Firma:	Fecha:

Public reporting burden of this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011).

Infection Prevention and Control Questions for Investigation of Mucormycosis Outbreak in BMT Unit Undergoing Construction

EXISTING PRECAUTIONS

- -What special precautions were taken for the construction period?
 - -all patients in unit 41 and unit 42
 - -Bone marrow transplant patients
 - -neutropenic patients?
 - -immunocompromised patients?
- -What barriers or protection from rest of hospital exist (i.e. anteroom or waiting area separating BMT unit)?
- -What precautions were taken when patients walk in the hallways? What precautions were taken when patients left the ward?

POTENTIAL EXPOSURES

- -Have you noticed any water damage, leaks, discoloration, moisture/condensation?
- -What equipment or supplies are used in the nose or mouths of patients? Where and how are they stored?
 - (i.e. nasal sprays, nasal cannula, masks, nebulizer machines, medicine/water for breathing tx)
- -Are any oral procedures done on the ward?
- -Where are linens laundered and stored? How are they delivered to the wards?
- -How are the units cleaned?
- -How are respiratory viral panels obtained?
- -How are patients transported off the units?

AIR SUPPLY

- -What is the difference in air quality of rooms on the ward?
- -What regular maintenance or upgraded precautions were done on the air supply (HEPA filters/air units)?
- -Was ward duct system/plumbing exposed to construction area? Was HVAC system in construction isolated?
- -Was vacuuming or air pressure systems used to protect air quality?
- -Any air leaks from the outdoors?
- -Was air supply shared between unit 41 and unit 42?
- -What are the air pressure differentials on unit 41 and unit 42?
- -How was air exhausted out of the construction area

CONSTRUCTION

- $\hbox{-}What other special precautions taken during construction?}\\$
- -Was construction site completely isolated from ward?
- -What kind of barriers were used to isolation construction area?
- -What holes existed in completely isolating construction?
- -Did any construction personnel have to access ward? If so, what precautions were used?
- -How long after construction were barriers removed? How were barriers and debris removed?
- -What cleaning was done after construction?
- -What air testing or monitoring was done during construction and before barriers were removed?
- -What was the flow of patient and construction traffic during the construction period?
- -How was negative pressure attained? How was it monitored?
- -How was demolition waste removed?

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

Patient Investigation #:
Form Approved
OMB No. 0920-1011
Exp. Date 03/31/2017

Data Abstraction Form (long-version):

Matched-Case Control Investigation of Mucormycosis Disease among Bone Marrow Transplant Patients

Patient initials: Patient Investigation #: Medical Record #:
Date of Birth:/
Phone #:
Reviewers Initials: Review Date:
Confirmed Case of Nosocomial Rhinocerbral or Pulmonary Mucormycosis Infection Rhinocerebral or pulmonary mucormycosis in a patient with a hematologic malignancy diagnosed by
histopathology or culture between January 1, 2014 – present with an admission to Hospital A for at least 5 days within the 30 days prior to date of clinical suspicion for mucormycosis defined as initiation of antifungal medications for treatment of suspected mucormycosis
Clinical suspicion for mucormycosis is defined as initiation of antifungal medications for treatment of suspected mucormycosis

Definition of his topathological confirmation

Histopathological examination showing hyphae consistent with a mucormycete from needle aspiration or biopsy specimen

Definition of culture confirmation

Positive culture result for a sample obtained by sterile procedure from normally sterile

Public reporting burden of this collection of information is estimated to average 90 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

Patient Investigation #:
Form Approved
OMB No. 0920-1011
Exp. Date 03/31/2017

Appendix 1: Case Abstraction Form

Section I:	Demographic and Admission Data
1. 2.	Date of Birth:/ Gender:
3.	Race: (select all that apply) white/Caucasian black/African-American
	☐ Asian, American ☐ Indian/Alaskan ☐ Hawaiian/Pacific Islander ☐ Not known
4.	Ethnicity: Hispanic non-Hispanic Not known
5.	Occupation:
6.	City of Residence: State of Residence:
7.	Date of clinical suspicion for mucormycosis (mm/dd/yy):/
Section II	: Underlying Medical Conditions and Risk Factors
8.	Underlying Conditions (active within 30 days prior to or at the time of clinical suspicion for mucormycosis)
9.	Diabetes? Yes No
	a. If yes, specify last Hemoglobin A1C level within 30 days prior to mucormycosis
	diagnosismmol/mol or Unknown
	Date of this HgA1C:/
	b. If yes, did the patient have Diabetic Ketoacidosis (DKA) during stay on unit? Yes No
10.	Iron Overload? ☐ Yes ☐ No
	a. If yes, specify levelµg/dLor ☐ Unknown
	b. If yes, check underlying disease
	☐ Hemochromatosis
	☐ Frequent Transfusion
	Other
11.	Previous fungal infections? Yes No
	a. If yes, which organism?
	\square Candida spp. \square Aspergillus \square Mucormycosis \square Histoplas mosis
	☐ Unknown ☐ Other
	b. If yes, date of diagnosis (mm/dd/yy):/ or
12.	Solid tumor malignancy? ☐ Yes ☐ No
	a. If yes, specify type:
13.	Solid organ transplant (ever)? ☐ Yes ☐ No
	a. If yes, specify type (select all that apply: ☐ Renal ☐ ☐ Liver ☐ ☐ Lung ☐ Heart
	Other (specify)
	b. If yes, date of most recent transplant (mm/dd/yy):/ or Unknown
14.	Aplastic anemia? ☐ Yes ☐ No

Patient	Investigation	#:
	Fo	orm Approved
	OME	3 No. 0920-1011
	Exp.	Date 03/31/2017

15.	Myelodys	plastic syndrome (e.g. RA, RARS, RAEB-1, RAEB-2, RCMD, RCMD/RS, 5q syndrome, CMML))?
	☐ Yes	□ No	
16.	Hematolog	gic malignancy?	
	a. If y	ves, check all that apply:	
	☐ Leu	kemia (if marked, indicate subtype below)	
		☐ Acute myeloid leukemia (AML) (e.g. M0-M7)	
		☐ Chronic myeloid leukemia (CML) (e.g. Chronic phase, Accelerated phase, Blast crisis)	
		☐ Acute lymphocytic leukemia (ALL) (e.g. L1-L3)	
		☐ Chronic lymphocytic leukemia (CLL) (e.g. B cell origin, T cell origin, Adult T cell leukemi	a,
		Sezary syndrome, Unclassified)	
		☐ Other	
		Unknown	
	☐ Hod	gkin's disease (e.g. Lymphocyte predominant, Lymphocyte rich, Nodular sclerosis, Hairy cell	
	leukemi	a, Mixed cellularity, Lymphocyte depleted, Large, granular lymphocyte leukemia)	
	☐ Non	-Hodgkin's lymphoma (e.g. B cell origin, T cell origin)	
	☐ Mul	tiple myeloma	
	Oth	ег	
	☐ Non	e	
Transplan	t-related his	story	
17.	Has the pa	atient had a hematopoietic stem cell transplant? Yes No	
	a.	If yes, check the type of transplant:	
		Allogeneic	
		If allogeneic, which type: Identical Sib Haploidentical MUD Cord blood	
		Autologous	
	b.	If transplant recipient, date of most recent transplant (mm/dd/yy):/	
	c.	If transplant recipient, last CD4count within 30 days prior clinical suspicion for mucormycosis	
		cells/mm ³ or Unknown	
18.	Has the pa	atient had Graft-versus-host disease (GVHD): Yes No	
	a.	If yes, did they have acute GVHD? Yes No	
		i. If yes, record grade (I-IV) or Unknown	
		ii. If yes, date of most recent acute GVHD diagnosis (mm/dd/yy):/ or \Box]
		Unknown	
		iii. If yes, is disease: Treated Untreated Unknown	
	b.	If yes, did they have chronic \square Yes \square No	
		i. If yes, check one: \square limited \square extensive \square unknown	

					E	Exp. Date 03/31/2017
		ii. If yes, date of most reco	ent chronic GVI	HD diagnosis (m	nm/dd/yy):	_/or 🗆
			Treated [Untreated	Unknown	
19		undergone chemotherapy in the				ormycosis (If ves
17.	_	notherapy agents in the Medication			spicion for mac	omycosis (ii yes,
20		had neutropenia (< 500 neutropl			or clinical susp	vicion for
20.	mucormycosis		iiiis pei iiiiii) w	min 30 days pii	or emilear susp	icion ioi
	•	es, total number of neutropenic d	ove within 20 d	lov poriod:	or \square	Unknown
21						
21.	weeks? \(\Boxed{\Delta}\) Yes	received systemic corticosteroid	is at avg dose≥	o.s mg/kg/day pi	ledinsone (or ec	quivalent) for > 2
	weeks? Its	□ NO				
Section II	I: Patient flow					
		sion during which mucormycosis	s was diagnosa	d2 (mm/dd/yyy):	/ /	/ /
22.		g, patient is still hospitalized	s was diagnose	u: (IIIII/uu/yy)	//	//
22		ient admitted from?				
_	Home	ent admitted nom?				
		/subacute care facility				
	_					
L -	☐ Other acute ca	ire nospitai				
L	Unknown	1	. C 114	.c. cn.,		
	_	ome, subacute care facility or acu	-			
24.	_	t have any inpatient hospitalization		-		
Г	_	on for mucormycosis? Note: incl	ude the admiss:	ion during which	the diagnosis v	was made.
_	□ No □ Unkı					
		ne patient flow table below with r		*		
	_	and including the admission du	-	_		
•	· -	ent moved rooms or units during				
	•	ng the same admission number. Į	•	•		•
	_	e document this in a separate row		lmission number.	The earliest ad	lmission within 30
a	lays of clinical su	uspicion should be denoted as ad	lmission #1))			
A	Admission #	Location	Room	Start a		Stop date
		Unit	Number	(mm/dd/	(yy)	(mm/dd/yy)
		☐ Unit 41 ☐ Unit 42		//_		/ / or
		☐ Unit 45				Ongoing
		☐ Other, specify				
		, 1 ,				

Patient Investigation #: Form Approved

OMB No. 0920-1011

					Form Approved OMB No. 0920-1011 Exp. Date 03/31/2017
	Unit 41	☐ Unit 42	/		/ or
	☐ Unit 45				Ongoing
	☐ Other, spec	cify			
	☐ Unit 41	☐ Unit 42	//		/ or
	☐ Unit 45				Ongoing
	☐ Other, spec	cify			
Section IV: Medica	tions and Procedures				
Medications					
25. Has pati	ent received immunosu	ppressive medications (inc	luding chemotherapy a	and GVHD tr	eatment) within 30
days of	clinical suspicion for m	ucormycosis? Yes	□ No		
a. If y	res, please complete the	e following table:			
Immunos u ppres	sant medications	Medication	Most recent dose	Total	Average daily
		Indication	prior to clinical	treatment	dose
			suspicion	days	(steroids only)
			(mm/dd/yy)		
☐ MEC	☐ Flu/Cyt/TBI	☐ Induction chemo	/		
☐ FLAG	☐ Intrathecal MTX	☐ Maintenance chemo	Unknown		
☐ Cyt/Daun	☐ Intrathecal Cyt	☐ GVHD			
☐ Solumedrol	☐ Prednisone	Other			
☐ Dexamethasone	☐ None				
Other					
☐ MEC	☐ Flu/Cyt/TBI	☐ Induction chemo	//		
☐ FLAG	☐ Intrathecal MTX	☐ Maintenance chemo	Unknown		
☐ Cyt/Daun	☐ Intrathecal Cyt	☐ GVHD			
Solumedrol	☐ Prednisone	☐ Other			
☐ Dexamethasone	☐ None				
Other					
☐ MEC	☐ Flu/Cyt/TBI	☐ Induction chemo	/		
□ FLAG	☐ Intrathecal MTX	☐ Maintenance chemo	Unknown		

☐ GVHD

Other__

☐ Intrathecal Cyt

☐ Prednisone

☐ Cyt/Daun

☐ Solumedrol

Other_

☐ Dexamethasone ☐ None

Patient Investigation #: ___

Patient Investigation #:
Form Approved
OMB No. 0920-1011
Exp. Date 03/31/2017

☐ Micafungin ☐ Posaconazole ☐	Itraconazole	☐ Treatm	ent	Unknown		Unkno	wn	☐ Ongoing ☐ Unknown
☐ Micafungin				Hinknown		Unknov	wn	☐ Ongoing
				I		1		
Amphotericin B	Fluconazole	Prophy	laxis	Start:/_	/	Stop:	//	Completed
Voriconazole								
Posaconazole	Itraconazole	☐ Treatm	ent				·· ··	Unknown
☐ Micafungin				Unknown		Unkno	wn	☐ Ongoing
Amphotericin B	Fluconazole	Prophy	laxis	Start:/_	/	Stop:	//	Completed
Antifungal	drug	Purpo	se	Start o			date (dd/yy)	Course Status at time of diagnosis
☐ Yes (fill out the table below, select one antifungal drug per row) ☐ No ☐ Unknown								
another fungal infection)? DO NOT include drugs given to treat mucormycosis.								
	that were given for reasons other than treatment of the mucormycosis infection (i.e. prophylaxis or treatment of							
			_		-	_	_	n for mucormycosis
Other								
Dexamethasone	☐ None							
☐ Solumedrol	☐ Prednisone							
Cyt/Daun	☐ Intrathecal (GVHD	nance chemo				
☐ FLAG	☐ Intrathecal I			nance chemo	Unkno	wn		
☐ MEC	□ Flu/Cyt/TB	<u> </u>	Inducti	on chemo	/	/		
Other	□ None							
☐ Solumedrol☐ Dexamethasone	☐ Prednisone ☐ None		Other_					
☐ Cyt/Daun	☐ Intrathecal (·	GVHD					
☐ FLAG	☐ Intrathecal I			nance chemo	_ Chkho	WII		
☐ MEC	☐ Flu/Cyt/TB			on chemo	Unkno	_/ wn		
Other								
☐ Dexamethasone	None							
☐ Solumedrol	☐ Prednisone		Other_					
☐ Cyt/Daun	☐ Intrathecal	Cyt 🗆 🗘	GVHD					
☐ FLAG	☐ Intrathecal I	мтх 🗆 п	Mainte	nance chemo	Unkno	wn		
☐ MEC	☐ Flu/Cyt/TB	I 📙 1	Inducti	on chemo	/	_/		

			Patient Investig	ation #:
				Form Approved
				OMB No. 0920-1011 Exp. Date 03/31/2017
				•
☐ Amphotericin B ☐ Fluco	onazole Prophylaxis	Start:/	Stop://	_
☐ Micafungin		Unknown	Unknown	Ongoing
Posaconazole Itracon	nazole Treatment			Unknown
Voriconazole				
☐ Amphotericin B ☐ Fluco	onazole Prophylaxis	Start:/	Stop:/	_ Completed
☐ Micafungin		Unknown	Unknown	Ongoing
☐ Posaconazole ☐ Itracon	nazole			Unknown
Voriconazole				
07 70111	1	6.1 6.11		
_	have administration of any	of the following products	to the oral or hasal cav	ities in the thirty days
	is? (Check all that apply)			
☐ Nasal Packin	g nasal saline spray	√	U Other	
☐ None				
_	have any inpatient respirate	ory therapies in the 30 day	s prior to clinical suspic	cion for
mucormycosis?				
☐ Yes ☐ No	Unknown			
a. If yes, check a	all that apply:			
□ NC O2	☐ NC O2 w/ humidifi	ied air 🔲 🗆 Nebulized	meds (SVN)	MDIs
☐ CPAP/BIP	AP Dther	☐ None	Unknown	
b. If 'yes' to SV	N or MDI, fill in the table			
Ž	,			
	Drug	Mode of Administrati	ion (SVN or MDI)	
				
D I				
Procedures		20.1	1	
_	have any procedures within	1 30 days prior to the clinic	al suspicion for mucorn	nycosis?
□ No □ Unknow				
☐ Yes (fill out the p	patient table below with all	l procedures within 30 day	s prior to clinical suspi	cion and including the

admission during which the diagnosis was made. Please choose one procedure per row. If a patient had the same

 $procedure\ on\ multiple\ occasions, please\ document\ each\ procedure\ on\ a\ separate\ row.\)$

Patient Investigation #:	
Form Approved	
OMB No. 0920-1011	
Exp. Date 03/31/2017	

Procedure	Procedure type (document for OMFS/Dental, ENT,	Date (mm/dd/yy)	Location/Unit	Procedure Room	If surgery or procedure, list orifices manipulate d
	radiology and				mampurateu
	GI procedures				
☐ Oral Intubation ☐ Nasal Intubation ☐ Oral Maxillary Facial/Dental ☐ ENT procedure ☐ Tracheostomy ☐ Bronchoscopy ☐ Radiology ☐ GI procedure			☐ OR ☐ ICU ☐ Ward ☐ IR ☐ Radiology ☐ GI suite ☐ Unknown ☐ Other		
Other					
☐ Oral Intubation ☐ Nasal Intubation ☐ Oral Maxillary Facial/Dental ☐ ENT procedure ☐ Tracheostomy ☐ Bronchoscopy ☐ Radiology ☐ GI procedure ☐ Other			☐ OR ☐ ICU ☐ Ward ☐ IR ☐ Radiology ☐ GI suite ☐ Unknown ☐ Other		
□ Oral Intubation □ Nasal Intubation □ Oral Maxillary Facial/Dental □ ENT procedure □ Tracheostomy □ Bronchoscopy □ Radiology □ GI procedure □ Other			☐ OR ☐ ICU ☐ Ward ☐ IR ☐ Radiology ☐ GI suite ☐ Unknown ☐ Other		

Patient	Investigation	#:
	Fo	orm Approved
	OME	3 No. 0920-1011
	Exp.	Date 03/31/2017

☐ Oral Intubation		//	□ OR □ ICU		
☐ Nasal Intubation			☐ Ward ☐ IR		
☐ Oral Maxillary			☐ Radiology		
Facial/Dental			☐ GI suite		
☐ ENT procedure			Unknown		
☐ Tracheostomy			Other		
Bronchoscopy					
☐ Radiology					
☐ GI procedure					
☐ Other					
☐ Oral Intubation			□ OR □ ICU		
☐ Nasal Intubation			☐ Ward ☐ IR		
☐ Oral Maxillary			Radiology		
Facial/Dental			☐ GI suite		
☐ ENT procedure			Unknown		
☐ Tracheostomy			Other		
Bronchoscopy					
☐ Radiology					
☐ GI procedure					
Other					
☐ Oral Intubation			□ OR □ ICU		
☐ Nasal Intubation			☐ Ward ☐ IR		
☐ Oral Maxillary			☐ Radiology		
Facial/Dental			☐ GI suite		
☐ ENT procedure			Unknown		
☐ Tracheostomy			Other		
☐ Bronchoscopy					
☐ Radiology					
☐ GI procedure					
Other					
☐ Yes	□ No □ Unkno				
a. If yes,		irst CT head or sinuses afte	er cunical suspicion of m	iucormycosis:	//
and fin	CHIES				

		Patient	Form Approve OMB No. 0920-1 Exp. Date 03/31/2
	oosis		-
	we a MRI brain within 30 days of		
☐ Yes ☐ No	Unknown		
a. If yes, please lis	t date of first MRI brain after clini	ical suspicion of mucormycos	is:/and
	oosis		·
for mucormycosis		view within 30 days before or nknown	30 days after clinical suspic
a. If yes, please co	Anatomical site	Mucormycosis	Pathology Technique
Date (IIIII da yy)	7 matorinear Site	mentioned in report	Tunology Teeninque
//	☐ Nasal cavity ☐ Palate	Yes	☐ Morphology
	☐ Orbit ☐ Lung	□ No	☐ Stain
	☐ Skin ☐ Brain	Unknown	Unknown
	☐ Other	☐ Other	☐ Other
	Unknown		
/	☐ Nasal cavity ☐ Palate	☐ Yes	☐ Morphology
	☐ Orbit ☐ Lung	□ No	☐ Stain
	☐ Skin ☐ Brain	☐ Unknown	Unknown
	☐ Other	Other	Other
	□Unknown		
//	☐ Nasal cavity ☐ Palate	Yes	Morphology
	☐ Orbit ☐ Lung	□ No	☐ Stain
	☐ Skin ☐ Brain	Unknown	Unknown
	Other	Other	Other
/ /	☐ Unknown ☐ Nasal cavity ☐ Palate	☐ Yes	☐ Morphology
 '	☐ Orbit ☐ Lung	□ No	□ Stain
	☐ Skin ☐ Brain	Unknown	Unknown
	Other	Other	Other
	Unknown	-	
·e	issue or aspirate specimens sent fo		

Patient Investigation #:
Form Approved
OMB No. 0920-1011
Exp. Date 03/31/2017

a. If yes, please complete table (do not include blood cultures):

Culture Date	Specimen Type	Result	Micro Technique
(mm/dd/yy)			
/	☐ Tissue, specify type:	☐ No growth of fungus☐ Growth of fungus,	☐ Morphology ☐ Thermotolerance
	☐ Aspirate	specify organism	Other
	☐ Sinus fluid/drainage		Unknown
	□ BAL		
	☐ Other		
/	☐ Tissue, specify type:	☐ No growth of fungus	☐ Morphology
		☐ Growth of fungus,	☐ Thermotolerance
	☐ Aspirate	specify organism	Other
	☐ Sinus fluid/drainage		☐ Unknown
	☐ BAL		
	Other		
/	☐ Tissue, specify type:	☐ No growth of fungus	☐ Morphology
		☐ Growth of fungus,	☐ Thermotolerance
	☐ Aspirate	specify organism	Other
	☐ Sinus fluid/drainage		☐ Unknown
	☐ BAL		
	Other		
//	☐ Tissue, specify type:	☐ No growth of fungus	☐ Morphology
		☐ Growth of fungus,	☐ Thermotolerance
	☐ Aspirate	specify organism	Other
	☐ Sinus fluid/drainage		☐ Unknown
	☐ BAL		
	Other		
tion VI: Treatment			

34. Did	the patient und	dergo surgica	l treatment :	for mucormy	ycosis? ∟	Yes	■ No	∟ Unl	knowi
---------	-----------------	---------------	---------------	-------------	-----------	-----	------	-------	-------

a. If yes, complete the following chart of all surgical treatments for mucormycosis within 30 days after clinical suspicion.

Patient Investigation #:
Form Approved
OMB No. 0920-1011
Exp. Date 03/31/2017

Date	Surgery	type					
(mm/dd/yy)				_			
/							
/							
/							
/							
/							
	perbaric oxygen therapy (HBO)?						
-	th an antifungal drug for their m	ucormycosis infection	? ∐ Yes	□ No □			
Unknown							
a. If yes, complete table:							
Antifungal drug	Route	Start dates (mm/dd/yy)	Total treatme nt days	Course Status			
Amphotericin B	□ IV	Start://		Finished			
☐ Posaconazole	□ РО	Unknown		☐ Ongoing			
Other, specify	☐ Topical administration☐ Unknown			□ Unknown			
☐ Amphotericin B	□ IV	Start://		☐ Finished			
☐ Posaconazole	□ РО	Unknown		Ongoing			
Other, specify	☐ Topical administration☐ Unknown			□ Unknown			
Amphotericin B	□ IV	Start://		Finished			
☐ Posaconazole	□ РО	Unknown		Ongoing			
Other, specify	☐ Topical administration☐ Unknown			Unknown			
37. Did the patient receive iron chelator therapy? ☐ Yes ☐ No ☐ Unknown a. If yes, which medication? ☐ Deferasirox ☐ Deferiprone ☐ None ☐ Other (specify)							
Section VII: Outcomes							
38. Was there extension of the	e disease from the original site o	bserved at surgical diag	gnosis?				
☐ Yes ☐ No	Unknown						
a. If yes, did disease exten	d to:						
Brain?							
Sinuses? Yes	□ No Jaw?	☐ Yes ☐ No					
Other?	☐ No If yes, specify						

		Patient Investi	gation #: Form Approved
			OMB No. 0920-1011 Exp. Date 03/31/2017
39. Did the patient suffer any complicaa. If yes, did patient develop:	tions?	Unknown	
Nerve Palsy? ☐ Yes ☐	☐ No	Vascular Event?	Yes □ No
Enucleation?	No Renal f	failure from mediations?	es 🗆 No
Other? Yes No	If yes, specify		
40. Status at discharge: Alive	☐ Deceased	☐ Unknown	
41. Current status:	☐ Deceased	☐ Unknown	
a. If deceased, date of death: (mm/d	d/yy)/		
b. If deceased, what was the cause	of death? Specify	or 🗌 Unknown	
c. If deceased, how was cause of de	eath determined? Ch	art Review Death Certifica	te 🗌 ICD-9
☐ Autopsy report ☐ Other_			
Section VIII: Symptoms/Signs			
42. When was the onset of symptoms? (mm/d	d/yy)/	or Unknown	
Please check all symptoms and signs which	h were documented wit	thin 30 days prior to clinical sus	picion for
mucormycosis			
Constitutional			
43. Fever? Yes No Unkn			
44. Headache? ☐ Yes ☐ No ☐ U	Inknown		
Ophthalmol ogic/Integument			
45. Reddish skin over nose? ☐ Yes	□ No □ Unknown		
46. Swollen skin over nose? ☐ Yes	□ No □ Unknown		
47. Proptosis? ☐ Yes ☐ No ☐ U	nknown		
Respiratory			
48. Nasal congestion? ☐ Yes ☐ No	Unknown		
49. Rhinorrhea? ☐ Yes ☐ No ☐	Unknown		
50. Dilated pupil? ☐ Yes ☐ No ☐	Unknown		
51. Nonreactive pupil? ☐ Yes ☐ No	Unknown		
52. Necrotic lesions visualized in mout	h?□ Yes □ No □	Unknown	
53. Necrotic lesions visualized within i	nares? Yes No	Unknown	
54. Edema of the nasal turbinates? ☐	Yes 🗌 No 🔲 Unkr	own	
55. Edema of the posterior pharynx?] Yes □ No □ Un	known	

56. Sputum production? ☐ Yes ☐ No ☐ Unknown

57. Hemoptysis? ☐ Yes ☐ No ☐ Unknown

	Patient Investigation #: Form Approved OMB No. 0920-1011 Exp. Date 03/31/2017
58. Epistaxis? ☐ Yes ☐ No ☐ Unknown	
59. Dyspnea? ☐ Yes ☐ No ☐ Unknown	
Neurologic	
60. Facial pain? ☐ Yes ☐ No ☐ Unknown	
61. Tinnitus? Yes No Unknown	
62. Ptosis of the eyelid? ☐ Yes ☐ No ☐ Unknown	
63. Cranial Nerve deficits? ☐ Yes ☐ No ☐ Unknown	
64. Alerted Mentation? ☐ Yes ☐ No ☐ Unknown	
65. Blindness of the eye? ☐ Yes ☐ No ☐ Unknown	

Nome E	ntrevistas	de Segu	imento i	na Cor	nunidade	OMB NO. 0920-101 Data de validade: 31/03/2017
			Sexo		Codigo do individuo	
Apelido	Idade			F		
Pai					Consentimento ver	bal obtido
Bairro						
25 de Junho	Caho	Vale de	Chitima 🔘 🤆	Suebuza		
Boroma	Catondo	Cawira E	B ⊚ C	Cadongolo		
Josina Machel	Cawira A	↑ 1 de Ma	io © C	Outro		
Teve alguns sintomas du	ırante as ultimas qı	uatro semanas?			•	
Voce foi atendido no ban	ico socorro ou cent	ro de saude por	causa dessas si	intomas?		-
Se sim, foi internado?		•	Data de inte	rnamento		
—Sintomas Neurologicas	;					
Marcar se o paciente tenh sabe." Escreve "ate agora				ltimas 4 sem	anas. Se o paciente nao s	aba, escreve "nao
Fraqueza generaliza	da [Dia de inicio		Data reso	olvido	
Fraqueza nos memb	ros [Dia de inicio		Data reso	olvido	
Perda de sensacao (maos ou pes) [Dia de inicio		Data reso	olvido	
Formigueiro	[Dia de inicio		Data reso	olvido	
Problemas de equilib	orio [Dia de inicio		Data reso	olvido	
Cefaleia	[Dia de Inicio		Data reso	olvido	
■ Tontura	[Dia de inicio		Data reso	olvido	
Visao embacada	[Dia de inicio		Data reso	olvido	
Perda da visão perife	érica [Dia de inicio		Data reso	olvido	
Perda de audicao	[Dia de inicio		Data reso	olvido	
Zumbido dos ouvido	s [Dia de inicio		Data reso	olvido	
Dificuldades de engo	olir [Dia de inicio		Data reso	olvido	
Perda da memoria		Dia de inicio		Data reso	olvido	
Dificuldades de sorri	r ou fechar dos ol f	inicio ai		Data reso	olvido	
■ Tremor		Dia de inicio		Data reso	olvido	
Convulsoes		Dia de inicio		Data reso	olvido	
Outras						

Formulário Aprovado

A carga de relatando publico desta colecta de informacao é estimado serem média 20 minutos por resposta, incluindo o tempo para revisar as instruções, a busca de fontes de dados que ja existem, a coleta e manutenção dos dados necessários e completar e rever a coleta de informações. Uma agência não poderá realizar ou patrocinar, e uma pessoa não é obrigada a responder a uma coleta de informações, a menos que mostra um número de controle atual e válido de OMB. Envie comentários sobre esta carga estimativa ou qualquer outro aspecto da recolha de informações, incluindo sugestões para reduzir esta carga para: CDC / ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333 E.U.A.; ATTN: PRA (0920-1011)

☐ Dor abdominal Dia de inicio Data resolv	ido
■ Nausea Dia de inicio Data resolvid	0
□ Vomitos Dia de inicio Data resolvi	ido
☐ Diarreia Dia de inicio Data resolvi	ido
Olhos amarelos Dia de inicio Data resolvi	ido
Cardiopulmonary	
Dor toraxica Dia de inicio	Data resolvido
Palpitacao Dia de inicio	Data resolvido
Dificultade de respiracao Dia de inicio	Data resolvido
Inchaco nas pernas Dia de inicio	Data resolvido
2.0 00	
Sintomas Gerais e Outros	
Rash ou outras manchas novas no pele (descrever) Dia de inicio	Data resolvido
Mudancas nos cabelos ou unhas (descrever) Dia de inicio	Data resolvido
Febre Dia de inicio	Data resolvido
Contusoes anormal Dia de inicio	Data resolvido Data resolvido
Contuspes anormal	
Contusoes anormal Dia de inicio	Data resolvido
Contusoes anormal Sangramento Dia de inicio Dia de inicio	Data resolvido Data resolvido
Contusoes anormal Dia de inicio	Data resolvido Data resolvido Data resolvido
Contusoes anormal Dia de inicio	Data resolvido Data resolvido Data resolvido
Contusoes anormal Dia de inicio	Data resolvido Data resolvido Data resolvido
Contusoes anormal Dia de inicio Sangramento Dia de inicio Quantidade de urina dimunuiu Dia de inicio Perda de appetite? Dia de inicio	Data resolvido Data resolvido Data resolvido
Contusoes anormal Dia de inicio Sangramento Quantidade de urina dimunuiu Perda de appetite? Dia de inicio Dia de inicio Dia de inicio Porda de inicio Voce ja se sente completamente curado dessa doenca?	Data resolvido Data resolvido Data resolvido
Contusoes anormal Dia de inicio Sangramento Dia de inicio Quantidade de urina dimunuiu Dia de inicio Perda de appetite? Dia de inicio Voce ja se sente completamente curado dessa doenca?	Data resolvido Data resolvido Data resolvido
Contusoes anormal Dia de inicio Sangramento Quantidade de urina dimunuiu Perda de appetite? Dia de inicio Dia de inicio Dia de inicio Porda de inicio Voce ja se sente completamente curado dessa doenca?	Data resolvido Data resolvido Data resolvido
Contusoes anormal Dia de inicio Sangramento Quantidade de urina dimunuiu Perda de appetite? Dia de inicio Dia de inicio Dia de inicio Porda de inicio Voce ja se sente completamente curado dessa doenca?	Data resolvido Data resolvido Data resolvido

Tainted Beverage Investigation Medical Record Abstraction

Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

Dados Clinicos dos Centros de Saude em Chitima e Songo

		Cod	igo individual
		Sex	«о———
Nome	Apelido	Idade O	M F
Barrio de residencia			
25 de Junho Caho	Vale de Chitima	© Guebuza	
BoromaCator		Cadongolo	
	a A 0 1 de maio	○ Outro	
Data de inicio dos sintomas	Hora de inicio dos sintomas	Hospital de	internamento
		Tiospital de	- Transferro
Data de internamento	Hora de interamento		•
		Desfecho	
Data de desfecho	Hora de desfecho	Destecno	_
			•
Sinais Vitais #1			
	Hora		
Pulso Pressao Arte	erial Sistólica	Frequência Respiratória	Temperatura (C)
Pressao Arte	erial Diastólica		
Sinais Vitais #2			
	Hora		
Pulso Pressao Art	erial Sistólica	Frequência Respiratória	Temperatura (C)
Pressao Art	erial Diastólica		
Tressau Are	eriai Biastolica		
Sinais Vitais #3			
Data I	Hora		
Pulso Pressao Arter	rial Sistólica	Frequência Respiratória	Temperatura (C)
Pressao Arter	rial Diastólica		

Dados Clinicos dos Centros de Saude em Chitima e Songo

Laboratório #	1					
Data	Hora	9				
WBC	Hgb	НСТ	Plt	PMN	Lymphocytes	MXD
Na	K	HCO3	Cl	BUN	Cr	Gluc
AST (SGOT)	ALT (SGPT)	TBili	Alk Phos	Total Protein	Albumin	
Laboratório #2	2					
Data	Hora	1	_			
WBC	Hgb	нст	Plt	PMN	Lymphocytes	MXD
Na	K	HCO3	CI	BUN	Cr	Gluc
AST (SGOT)	ALT (SGPT)	TBili	Alk Phos	Total Protein	Albumin	
Outros Resulta	doc Laborato	wiste				
Outros Resulta	ados Laborato	riais				
Problemas M	édicos		Me	dicamentos e	m Casa	

Dados Clinicos dos Centros de Saude em Chitima e Songo

Sintomas			
Cefaleia] Dor abdominal	Tosse	Febre
Tontura] Náusea	Dificuldade em respirar	Agitacao
Parestesias] Vómitos	Dor torácica	Convulsos
Fraqueza] Diarréia	Palpitacao	■ Tremor
Outras Sintomas			
Se sim, quais sintoma	s?		
Exame Físico			
Ataxia	Ternura abdominal	Dispneia	Agitacao
Diminuição da sensação	Vómitos Vómitos	Roncos	Coma
Fraqueza muscular	Diarréia	Edema nas pernas	Convulsos
Reflexos diminuídos	Vômito sanguinolento	Icterícia	Tremor
Outros achados			
Se sim, quais achados?			
Narrativa			
Intervenções			

Tainted Beverage Questionnaire

Follow up Interviews in the Community

Patient ID

First Name, Last Name, Age, M/F

Neighborhood of residence (radio button list)

Have you had other symptoms during the last 4 weeks? (drop down Y/N)

Have you been seen at the first aid clinic or health center because of these symptoms? (dropdown Y/N)

If yes, were you hospitalized? (dropdown Y/N) / Date of hospitalization:

Neurologic symptoms

Checkboxes:

Weakness - Date of onset/Date of resolution

Generalized weakness – Date of onset/Date of resolution

Extremity weakness - Date of onset/Date of resolution

Loss of sensation - Date of onset/Date of resolution

Paresthesias - Date of onset/Date of resolution

Problems with equilibrium - Date of onset/Date of resolution

Headache - Date of onset/Date of resolution

Dizziness - Date of onset/Date of resolution

Visual changes - Date of onset/Date of resolution

Blurry vision - Date of onset/Date of resolution

Double vision - Date of onset/Date of resolution

Loss of peripheral vision - Date of onset/Date of resolution

Hearing loss - Date of onset/Date of resolution

Buzzing in the ears - Date of onset/Date of resolution

Difficulty swallowing - Date of onset/Date of resolution

Memory loss - Date of onset/Date of resolution

GI symptoms

Checkboxes:

Abdominal pain - Date of onset/Date of resolution

Nausea - Date of onset/Date of resolution

Vomiting - Date of onset/Date of resolution

Diarrhea - Date of onset/Date of resolution

Yellow eyes - Date of onset/Date of resolution

Cardiopulmonary

Checkboxes:

Chest pain - Date of onset/Date of resolution

Palpitations - Date of onset/Date of resolution

Difficulty breathing - Date of onset/Date of resolution

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

General and other symptoms

Checkboxes:

Fever - Date of onset/Date of resolution
Chills - Date of onset/Date of resolution
Leg swelling - Date of onset/Date of resolution
Bruising - Date of onset/Date of resolution
Bleeding - Date of onset/Date of resolution
Decreased urine output - Date of onset/Date of resolution
(ADD) Loss of appetite - Date of onset/Date of resolution

Do you feel that you are completely cured of this disease? (dropdown Y/N) If no, are these symptoms affecting your activities of daily living?

Notes/other (free text)

Tainted Beverage - Medical Record Abstraction

Clinical data of the Health Centers in Chitima and Songa

Patient ID

First Name, Last Name, Age, M/F

Neighborhood of residence (radio button list)

Date of symptom onset, time of symptom onset

Date of hospitalization, hour of hospitalization

Where hospitalized (drop down: Chitima/Songo/Other)

Date of disposition, hour of disposition

Final disposition (drop down: discharged home, transferred, left AMA, died, no information)

<u>Vital Signs #1:</u> Date, hour, pulse, SBP, DBP, RR, temp <u>Vital Signs #2:</u> Date, hour, pulse, SBP, DBP, RR, temp <u>Vital Sings #3:</u> Date, hour, pulse, SBP, DBP, RR, temp

<u>Laboratory Data #1:</u> Date, hour, WBC, Hgb, Hct, PIt, PMN%, Lymph%, MXD% (eos/baso/monocytes), Na, K, CI, HCO3, CI, BUN, Cr, Gluc, AST, ALT, TBili, Alk Phos, TP, Alb

<u>Laboratory Data #2:</u> Date, hour, WBC, Hgb, Hct, PIt, PMN%, Lymph%, MXD% (eos/baso/monocytes), Na, K, CI, HCO3, CI, BUN, Cr, Gluc, AST, ALT, TBili, Alk Phos, TP, Alb

<u>Laboratory Data #3:</u> Date, hour, WBC, Hgb, Hct, PIt, PMN%, Lymph%, MXD% (eos/baso/monocytes), Na, K, CI, HCO3, CI, BUN, Cr, Gluc, AST, ALT, TBili, Alk Phos, TP, Alb

Other laboratory data (free text, consider adding malaria testing as a separate entry)

Medical problems (free text):

Home medications (free text):

Symptoms (checkboxes):

Headache, dizziness, paresthesias, weakness, abdominal pain, nausea, vomiting, diarrhea, cough, breathing difficulties, chest pain, palpitations, fever, agitation, convulsions, tremor, other symptoms (if yes, which other symptoms)?

Physician exam (checkboxes):

Ataxia, diminished sensation, muscle weakness, diminished reflexes, abdominal tenderness, vomiting, diarrhea, hematemesis, dyspnea, rhonchi, leg edema, icterus, agitation, coma, convulsions, tremor

Narrative (free text):

Interventions (free text):

Public reporting burden of this collection of information is estimated to a verage 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74 Atlanta, Georgia 30333; ATTN: PRA (0920-1011)

Exposure History for Blood Donors

LAST I	NAME:		FIRST NAM	E:	
SEX:	Female DATE OF F	BIRTH:/	AGE		
RACE:	<u>₩</u> hite	□ PICC POLICS ia E THOME	rITY: □Hispanic □	Non-Hispanic	Uhknown
PHONI	F·() -				
HOME	ADDRESS STREET:				
CITY:_		STATE:	ZIP:		
1.	What is your occupation (job title)?			
2.	Were you on the inspection	n tour on January 20-23	??Yes	_No	
3.	Did you work with rhesus	s macaque IL38 or rhes	sus macaque 1b 2	22?	
	Husbandry?	Yes	No		Maybe/Unsure
	Treatment of sick animal?	Yes	No		Maybe/Unsure
	Necropsy?		No		 Maybe/Unsure
	Clinical Pathology?	Yes			Maybe/Unsure
	Other (specify)				
	Have you worked in the T. Have you previously work YesNo If yes, please explain any p	xed with Burkholderia ps Maybe/Un	seudomallei?		waybe/ onsure
6.	Did you exit the vehicle w	hile inside the facility? _	Yes	No	Maybe/Unsure
7.	Were you in the van drive	n by Skip Bohm or by Jin	n Blanchard on d	ay 1 (circle).	
8.	Did you:				
	Area	8. a. Look from outside?	8. b. Enter inside?	8. c. Did you too anything ir	
	Necropsy Antiroom				
-	Necropsy Suite		-		
-	Visit sample transfer area Animal Clinic				
-	Other Areas				
	III		<u> </u>	_1	J

or water while on	the tour?	YesNo	Maybe/Unsure
C 11 · 1 ·	1	1 , .	. 1 . 6 1: 6
e following chronic e?	conditions t	hat can increase y	our risk of disease from
	Yes	No	Maybe/Unsure
lney disease	Yes	No	Maybe/Unsure
	Yes	No	Maybe/Unsure
nancy			
such as leukemia)	Yes	No	Maybe/Unsure
utrophil dysfunctio	n		•
od cell count)	Yes	No	Maybe/Unsure
se (asthma,			
hysema,			
	Yes	No	Maybe/Unsure
	Yes	No	Maybe/Unsure
Long-term steroid use		No	Maybe/Unsure
Other form of immunosuppression		No	Maybe/Unsure
aturally, including:	_		
Dates of Visit	Working in	n Soil or Water	
nave in your home	or regularly	interact with? If po	ossible include species and
	e following chronic e? Iney disease nancy such as leukemia) utrophil dysfunction of cell count) se (asthma, ohysema, dor been deployed aturally, including: ingapore, Vietnam, adagascar and Caribbean Dates of Visit	e following chronic conditions to e? Yes diney diseaseYesYes nancy such as leukemia)Yes utrophil dysfunction od cell count)Yes se (asthma, ohysema, Yes Yes useYes unosuppressionYes d or been deployed during militaturally, including: ingapore, Vietnam, Malaysia, Buadagascar a and Caribbean Dates of Visit Working in	e following chronic conditions that can increase ye? YesNo diney diseaseYesNoYesNo nancy such as leukemia)YesNo utrophil dysfunction od cell count)YesNo se (asthma, ohysema, YesNoYesNoYesNo useYesNo unosuppressionYesNo di or been deployed during military service to area aturally, including: ingapore, Vietnam, Malaysia, Burma, Vietnam, Taiadagascar a and Caribbean

Risk Assessment for individuals who may have had contact with Burkholderia pseudomallei

Name	e:Department:
Date o	completed:Contact phone number:
	se complete and return to Occupational Health as soon as possible,
<u>PLEA</u>	SE CHECK ALL APPROPRIATE BOXES:
LOW	RISK
	Inadvertent opening of a lid of an agar plate growing <i>B. pseudomallei</i>
	Inadvertent sniffing of agar plate growing B. pseu domallei
	Splash event leading to visible contact of <i>B. pseudomallei</i>
	Spillage of small volume of liquid culture within a functioning biologic safety cabinet
	Contamination of intact skin with culture
HIGH	RISK
	The presence of any predisposing condition without proper PPE (personal protective equipment) diabetes mellitus; chronic liver or kidney disease; alcohol abuse; long-term steroid use; hematologic malignancy; neutropenia or neutrophil dysfunction; chronic lung disease (including cystic fibrosis); thalassemia; any other form of immunosuppression
	Needlestick or other penetrating injury with implement contaminated with
	B. pseudomallei
	Bite or scratch by experimental animal infected with B. pseudomallei
	Splash event leading to contamination of mouth or eyes
	Generation of aerosol outside biologic safety cabinet (e.g., sonication, centrifuge incident)
Ackr	nowledgements:
	I do not believe I have any of the above low or high risk factors.
	I have had the opportunity to have all of my questions answered by Occupational Health
	I have had the opportunity to have all of my questions answered by the Office of Environmental Health and Safety
	I have had the opportunity to have all of my questions answered by the Office of Biosafety
	I am aware that I can contact Occupational Health at 985.966.6515 or the infectious disease department at Tulane at 504.988.5263 if I develop any symptoms of infection.
	I would like to request a private counseling session with (circle one/or more) Biosafety OEHS Occupational Health
Empl	oyee Signature: